skip to content
Primary navigation


Drug - Firazyr (icatibant) [Shire]

January 2012

Therapeutic area - Hereditary Angioedema

Approval criteria

  • Patient is ≥18 years of age AND
  • Patient has a diagnosis of hereditary angioedema AND
  • Patient has a history of acute abdominal and/or laryngeal/facial attacks AND
  • Patient has a documented intolerance to OR treatment failure with Cinryze or Beirnert AND
  • Patient has not taken an ACE inhibitor or estrogen replacement therapy in the last 1 month AND
  • Patient is having <4  acute HAE attacks per month

Limitations for use

Firazyr is limited to the ACUTE treatment of abdominal and/or laryngeal/facial HAE attacks.  Therefore, maintenance treatment is not authorized and only 3 syringes per month will be allowed. If patients are having greater than 1 attack per week, consider danzol maintenance therapy.  


Exceptions may be granted, on a case by case basis, for patients that do not have adequate access to Cinryze or Beirnert because they reside in a remote geographical region of the state with limited access to acute care facility.

Background information

Firazyr (icactibant) is a bradykinin B2 receptor antagonist indicated for the treatment of ACUTE attacks of hereditary angioedema (HAE) in adults 18 years of age and older.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top